Credit Suisse Ag Arcus Biosciences, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 47,298 shares of RCUS stock, worth $723,186. This represents 0.0% of its overall portfolio holdings.

Number of Shares

47,298

Previous 47,298 -0.0%

Holding current value

$723,186

Previous $903,000 1.22%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$13.43 - $19.63 $51,141 - $74,751	3,808 Added 8.76%	47,298 $903,000
Q3 2023 Nov 13, 2023	SELL	$17.62 - $23.54 $223,033 - $297,969	-12,658 Reduced 22.54%	43,490 $780,000
Q2 2023 Aug 11, 2023	BUY	$16.97 - $22.03 $365,788 - $474,856	21,555 Added 62.31%	56,148 $1.14 Million
Q1 2023 May 10, 2023	SELL	$15.96 - $23.15 $46,060 - $66,810	-2,886 Reduced 7.7%	34,593 $630,000
Q4 2022 Feb 13, 2023	SELL	$19.7 - $35.71 $29,668 - $53,779	-1,506 Reduced 3.86%	37,479 $775,000
Q3 2022 Nov 10, 2022	BUY	$23.23 - $30.07 $221,892 - $287,228	9,552 Added 32.45%	38,985 $1.02 Million
Q2 2022 Aug 12, 2022	SELL	$17.23 - $37.73 $45,280 - $99,154	-2,628 Reduced 8.2%	29,433 $746,000
Q1 2022 May 16, 2022	SELL	$28.92 - $41.83 $49,829 - $72,073	-1,723 Reduced 5.1%	32,061 $1.01 Million
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $22,876 - $35,334	729 Added 2.21%	33,784 $1.37 Million
Q3 2021 Nov 12, 2021	BUY	$26.93 - $37.68 $66,974 - $93,710	2,487 Added 8.14%	33,055 $1.15 Million
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $40,995 - $64,457	-1,802 Reduced 5.57%	30,568 $834,000
Q1 2021 May 14, 2021	SELL	$26.16 - $41.39 $842,011 - $1.33 Million	-32,187 Reduced 49.86%	32,370 $909,000
Q4 2020 Feb 12, 2021	SELL	$17.0 - $32.36 $648,210 - $1.23 Million	-38,130 Reduced 37.13%	64,557 $1.68 Million
Q3 2020 Nov 13, 2020	BUY	$17.14 - $25.47 $625,490 - $929,476	36,493 Added 55.13%	102,687 $1.76 Million
Q2 2020 Aug 12, 2020	BUY	$13.97 - $36.56 $718,435 - $1.88 Million	51,427 Added 348.26%	66,194 $1.64 Million
Q1 2020 May 13, 2020	BUY	$8.78 - $19.28 $29,369 - $64,491	3,345 Added 29.29%	14,767 $206,000
Q4 2019 Feb 12, 2020	SELL	$7.33 - $10.79 $42,821 - $63,035	-5,842 Reduced 33.84%	11,422 $115,000
Q3 2019 Nov 12, 2019	BUY	$6.44 - $10.18 $12,087 - $19,107	1,877 Added 12.2%	17,264 $157,000
Q2 2019 Aug 14, 2019	SELL	$7.29 - $13.38 $20,689 - $37,972	-2,838 Reduced 15.57%	15,387 $122,000
Q1 2019 May 14, 2019	BUY	$8.95 - $12.49 $44,714 - $62,400	4,996 Added 37.77%	18,225 $227,000
Q4 2018 Feb 13, 2019	BUY	$9.74 - $14.5 $128,850 - $191,820	13,229 New	13,229 $143,000

Others Institutions Holding RCUS

# of Institutions

207

Shares Held

49M

Call Options Held

173K

Put Options Held

151K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.1B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account